TDI-10229

TDI-10229

T655284-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

TDI-10229 is a potent and orally bioavailable inhibitor of soluble adenylyl cyclase (sAC, ADCY10) . TDI-10229 displays nanomolar inhibition of sAC in both biochemical and cellular assays ( IC 50 of 195 nM) and exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound In Vitro TDI-10229 exhibits good permeability with an IC 50 of 92 nM for human 4-4 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo TDI-10229 (5 mg/kg; p.o.) treatment shows the C max , AUC and MRT were 15.5 μM, 94 μg h/mL and 3.95 hours, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MouseDosage: 20 mg/kg Administration: P.o.(Pharmacokinetic Analysis) Result: The C max , AUC and MRT were 15.5 μM, 94 μg h/mL and 3.95 hours, respectively. IC50& Target:IC 50 : 195 nM (sAC)

TDI-10229 是一种口服生物活性强的可溶性腺苷酸环化酶（sAC，ADCY10）抑制剂。TDI-10229 在生化和细胞试验中对 sAC 都表现出纳摩尔级的抑制作用（IC 50 为 195 nM），并表现出小鼠药代动力学特性，可用于小鼠的药代动力学研究。

2810887-45-5(DMSO)

C16H16ClN5

313.78 g/mol

CC1=C(C(C2=CC(Cl)=NC(N)=N2)=NN1C)CC3=CC=CC=C3